.25mg of semaglutide Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) including heart disease Wegovy (Semaglutide) Weight Loss Injection

Complementary approaches may include: Behavioral therapy or weight management counseling Sleep optimization (79 hours nightly) Stress management techniques Evaluation and treatment of coexisting conditions (insulin resistance, sleep apnea, depression) FDA-approved oral weight loss medications (orlistat, phentermine/topiramate ER, naltrexone/bupropion) as alternatives to injectables (note: phentermine monotherapy is approved for short-term use only) Patients should maintain realistic expectationsweight loss may be slower with hypothyroidism, even when well-controlled

Researchers often examine it in models involving neuronal signaling, synapse formation, and learning-related pathway behavior

ScienceDirect, doi:10.1016/j.neuroscience.2013.04.060

These drugs, derived from the hormone glucagon-like peptide-1, enhance insulin secretion, delay gastric emptying, reduce appetite, and promote weight loss [6]

Tracheal intubation was performed to make the rats breathe independently